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Supplementary Figure 1 | Simultaneous generation of non-neural oral ectoderm 
and hypothalamic tissue in three-dimensional human embryonic stem cell (hESC) 
culture. 
(a) Schematic diagram of mouse pituitary development, sagittal view. (b) Schematic 
diagram of serum-free floating culture of embryoid body-like aggregates with quick 
reaggregation (SFEBq) culture. (c-e) Immunostaining of a day-24 aggregate without 
smoothened agonist (SAG) treatment for FOXG1 (c), TUJ (d) and N-cadherin (NCAD; 
e). The aggregate without SAG co-expressed FOXG1, TUJ and NCAD, indicating that 
the telencephalic neuroectoderm (NE) was induced. c and d; the same section, c and e; 
serial sections. (f,g) Non-neural oral ectoderm (pan-Cytokeratin+; f) also expressed 
E-cadherin (ECAD; white; g). (h-k) Induced RX::Venus+ tissue expressed the neural 
markers NCAD (i) and TUJ (j), but not the retinal marker CHX10 (k). (l) Atypical 
kinase C (aPKC) immunostaining of a sagittal section of the E13.5 mouse pituitary 
primordium demarcated by a white dotted line and oral ectoderm (arrowheads). The 
is a magnification of the white outlined area. (m) The number of Rathke’s pouch-like 
structures (LHX3+) of human versus mouse ESC aggregates (per 8 aggregates; hESC; n 
4, mESC; n = 3 experiments). n.s., not significant. Error bars represent s.e.m. Student’s 
t-test. Scale bars; 200 μm (c-e); 50 μm (f-k).  
 
Supplementary Figure 2 | Roles of fibroblast growth factor (FGF) and hedgehog 
signals in the hESC culture for the differentiation of PITX1+ and LHX3+ 
epithelium. 
(a,b) The endogenous expression of FGF8 (a) and FGF10 (b) during days 15-27 in the 
aggregates treated or untreated with SAG (2 μM) and bone morphogenetic protein 4 
(BMP4, 5 nM; qPCR analysis; n = 3 experiments). (c,d) The aggregates treated with 
SAG (2 μM) and BMP4 (5 nM) expressed PITX1 and LHX3, but FGF inhibitor 
treatment, PD173074 (10 μM) and SU5402 (0.5 μM) on days 15-27, decreased their 
expression on day 27 (qPCR; n = 3 experiments). (e,f) qPCR analysis for expression of 
GLI1. SFEBq culture on day 8. SAG treatment increased the GLI1 expression, but 
treatment with GLI inhibitors (HPI-1 at 50 μM for 48 hours; GANT61 30 μM for 36 
hours) decreased GLI1 expression of the SAG-treated aggregates (n = 3 experiments). 
(g,h) Inhibition of PITX1 (g) and LHX3 (h) induction (on day 27) by treating hESC 
aggregates with the GLI inhibitors during days 6-27 (qPCR; n = 3). (i,j) PITX1+ oral 
ectoderm (red) alone did not express LHX3 (white). (i) on day 28. (j) on day 53. (These 
aggregates, which consisted of only oral ectoderm, were quite rare in our culture.) Error 
bars represent s.e.m. * P < 0.05, ** P < 0.01, *** P < 0.001 using one-way ANOVA with 
Bonferroni’s test (a-h). Scale bars, 50 μm (i); 100 μm (j). 
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(white; b) expressed pituitary progenitor marker ISL1/2 (red; c), on day 30. (d) Culture 
protocol for adrenocorticotropic hormone (ACTH)-producing cells. (e) Double-staining 
of a day-67 aggregate for ACTH (green) and PITX1 (red). (f-k) Induced ACTH+ cells 
expressed the corticotroph marker PC1/3 (f-h) but not the melanotroph marker PC2 
(i-k). (l) Schematic of pituitary lineage development in vivo. (m,n) ACTH+ cells (green; 
m) expressed corticotropin releasing hormone receptors (CRH-R; n). (o) Culture 
protocol for growth hormone (GH)-secreting cells. DX, dexamethasone. (p) A human 
ESC aggregate immunostained for GH (green) and PITX1 (red). (q) Immunostaining of 
day-84 dexamethasone-treated aggregates for GH (green) and the lineage marker 
POU1F1 (red). (r) Prolactin (PRL; green) co-expressed with PITX1 (red) in hESC 
aggregates. (s-u) The majority of hESC-derived gonadotoropic cells co-expressed 
luteinizing hormone (LH; green) and follicle stimulating hormone (FSH; red). (v,w) 
Immunostaining of aggregates derived from a hESC line, KhES-3. (v) LHX3 (red) and 
pan-Cytokeratin (white). (w) ACTH (red), ECAD (white) and RX (green). In this report, 
all the hESC-aggregates’ data except for Supplementary Fig. 3s,t was derived from the 
KhES-1 cell line. Scale bars, 50 μm (a-c,e-k,p,r); 10 μm (m,n,q); 20 μm (s-w). 
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the day-94 aggregates cultured in hyperoxic (40% O2) condition secreted more GH versus 
control (n = 7). (g) Pituitary epithelial lesion excised from hESC aggregates, i.e. NE and 
debris were removed to reduce the graft volume. (h) The grafts 10 days after 
transplantation under the mouse renal capsule. (i) Increased blood corticosterone levels of 
wild-type SCID mice 60 min after intraperitoneal administration of human ACTH (5 
ng/g; n = 6 experiments). Scale bars, 50 μm (d,e); 200 μm (g). Error bars represent s.e.m. 
* P < 0.05, ** P < 0.01, *** P < 0.001 using one-way ANOVA with Bonferroni’s test (b) 
and Student’s t-test (f,i). 
 
 
 
Supplementary Figure 5 | The specificity of antibodies. 
(a-c) The anti-human LHX3 antibody was raised against a synthetic peptide whose 
amino acid sequence was nearly the same in human and mouse. The anti-human TBX19, 
and POU1F1 antibodies were raised against synthetic peptides whose amino acid 
sequence was the same in human and mouse. These antibodies (LHX3; a, TBX19; b, 
POU1F1; c) selectively recognized mouse embryonic adenohypophysis. (d-f) The 
specificity of anti-RX antibody was confirmed by immunostaining of RX::Venus hESC 
reporter line-derived neural retina. Scale bars, 50 μm (a-c); 200 μm (d-f). 
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